Aequus Pharmaceuticals (CVE:AQS-OTCQB: AQSZF) Chairman and CEO Doug Janzen joined Steve Darling from Proactive Vancouver as the company released their 2019 financial numbers which saw Aequus set a revenue record in the 4th quarter.
Janzen also discussed 2020 and where he sees the best opportunities for growth including the lucrative dry eye market and their partnership with Medicom.
Price: 0.265 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...
Industry & services
Prev article
